Holen Sie sich die Stockscreener-App
15.82
5.82%
0.87
Handel nachbörslich:
15.76
-0.06
-0.38%
Schlusskurs vom Vortag:
$14.95
Offen:
$14.94
24-Stunden-Volumen:
2.46M
Relative Volume:
1.89
Marktkapitalisierung:
$1.75B
Einnahmen:
$-665.00K
Nettoeinkommen (Verlust:
$-144.74M
KGV:
-10.19
EPS:
-1.5527
Netto-Cashflow:
$-123.48M
1W Leistung:
+23.98%
1M Leistung:
+14.22%
6M Leistung:
+24.67%
1J Leistung:
+361.22%
1-Tages-Spanne:
$14.90
$16.20
1-Wochen-Bereich:
$12.90
$16.20
52-Wochen-Spanne:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-682-0917
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.82 | 1.65B | -665.00K | -144.74M | -123.48M | -1.5527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | Stifel | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - gurufocus.com
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 3.52% on Apr 2 - gurufocus.com
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion - Sahm
Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Australia
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9%Still a Buy? - MarketBeat
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment - Insider Monkey
Buyback Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard) - Stock Titan
Market Recap: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesEarnings Recap Summary & Fast Gain Swing Alerts - baoquankhu1.vn
AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - za.investing.com
H.C. Wainwright reiterates Amylyx stock rating on trial progress - Investing.com
Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks
Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union
Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView
Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan
Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus
Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn
Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN
Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union
How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks
First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat
Commodore Capital Boosts Stake in Amylyx Pharmaceuticals - National Today
Commodore Capital LP Purchases Shares of 4,075,478 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Down 3.06% on Mar 13 - GuruFocus
Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Gap DownHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
Amylyx (NASDAQ: AMLX) Co-CEO receives new RSU and stock option grants - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 17.82% to 15.17 - MSN
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 02 '26 |
Sale |
14.48 |
29,282 |
424,120 |
3,334,683 |
| Bedrosian Camille L | Chief Medical Officer |
Mar 02 '26 |
Sale |
14.58 |
6,461 |
94,205 |
169,295 |
| FRATES JAMES M | Chief Financial Officer |
Mar 02 '26 |
Sale |
14.52 |
7,909 |
114,851 |
165,638 |
| Mazzariello Gina | Chief Legal Officer |
Mar 02 '26 |
Sale |
14.52 |
6,844 |
99,378 |
134,430 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):